Scarica l'app Stockscreener
9.20
9.36%
-0.95
Dopo l'orario di chiusura:
9.15
-0.05
-0.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.15
Aprire:
$10.2
Volume 24 ore:
1.94M
Relative Volume:
0.56
Capitalizzazione di mercato:
$652.28M
Reddito:
-
Utile/perdita netta:
$-117.81M
Rapporto P/E:
-4.8936
EPS:
-1.88
Flusso di cassa netto:
$74.30M
1 W Prestazione:
-19.30%
1M Prestazione:
+16.90%
6M Prestazione:
+170.59%
1 anno Prestazione:
+20.58%
Intervallo 1D:
$9.19
$10.24
Intervallo di 1 settimana:
$9.19
$11.71
Portata 52W:
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
Nome
Omeros Corporation
Settore
Industria
Telefono
206-676-5000
Indirizzo
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Confronta OMER con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
9.20 | 719.64M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
| 2022-12-08 | Downgrade | UBS | Buy → Neutral |
| 2022-11-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Downgrade | Maxim Group | Buy → Hold |
| 2021-10-01 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-09-27 | Iniziato | JP Morgan | Neutral |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-08-21 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-14 | Reiterato | Maxim Group | Buy |
| 2019-05-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-03-05 | Downgrade | Needham | Buy → Hold |
| 2017-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2017-05-11 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Reiterato | Maxim Group | Buy |
| 2017-03-17 | Reiterato | Needham | Buy |
| 2016-11-16 | Reiterato | Wedbush | Outperform |
| 2016-11-10 | Reiterato | Needham | Buy |
| 2016-08-10 | Reiterato | Maxim Group | Buy |
| 2016-06-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2016-03-02 | Reiterato | Needham | Buy |
| 2016-02-29 | Reiterato | Wedbush | Outperform |
| 2015-11-11 | Reiterato | Needham | Buy |
| 2015-08-18 | Reiterato | WBB Securities | Strong Buy |
| 2015-08-10 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Omeros Corporation Borsa (OMER) Ultime notizie
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN
Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat
Omeros (NASDAQ:OMER) Trading Down 5.1%Here's What Happened - MarketBeat
Omeros Corporation (OMER): Novo Nordisk deal creating buzz - MSN
Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz - Insider Monkey
11 Best Micro-Cap Stocks to Invest in According to Analysts - Insider Monkey
Omeros Corporation's (NASDAQ:OMER) Shift From Loss To Profit - Yahoo Finance
Do You Believe Omeros Corporation’s (OMER) New Monoclonal Antibody Has Strong Chances of Approval? - Insider Monkey
Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Omeros Completes Major Asset Deal with Novo Nordisk - MSN
Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential? - MSN
Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call - MSN
Omeros (NASDAQ:OMER) Stock Price Up 8.2%Still a Buy? - MarketBeat
Can Omeros Corporation stock outperform in 2025 bull marketJuly 2025 Update & Short-Term High Return Ideas - Newser
Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital - MarketBeat
Omeros Shares Jump After Finalizing $340 Million Novo Nordisk Deal - MSN
Aug Sentiment: Is Omeros Corporation stock attractive for income investorsMarket Volume Report & Smart Allocation Stock Tips - moha.gov.vn
How Omeros Corporation stock performs in weak economyChart Signals & Entry Point Confirmation Alerts - Newser
Omeros (OMER) Receives Consistent 'Buy' Rating from D. Boral Cap - GuruFocus
Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart - MSN
Omeros (OMER) Secures $2.1B Deal with Novo Nordisk - GuruFocus
Omeros Closes Asset Purchase, Licensing Deal With Novo Nordisk for Zaltenibart - MarketScreener
Omeros, Novo Nordisk Close Up to $2.1B Deal for Rare Disease Drug Zaltenibart, NOVO Stock - Somos Hermanos -
Omeros receives $240 million upfront from Novo Nordisk deal By Investing.com - Investing.com Canada
Omeros receives $240 million upfront from Novo Nordisk deal - Investing.com
Omeros stock surges after closing $340 million deal with Novo Nordisk - Investing.com Australia
Omeros stock surges after closing $340 million deal with Novo Nordisk By Investing.com - Investing.com South Africa
Omeros closes asset purchase and license deal with Novo Nordisk for MASP-3 inhibitor zaltenibart - marketscreener.com
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Yahoo Finance
Omeros Corporation (NASDAQ:OMER): When Will It Breakeven? - simplywall.st
What catalysts could drive Omeros Corporation stock higher2025 Short Interest & Weekly Top Stock Performers List - moha.gov.vn
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Omeros (NASDAQ:OMER) Shares Pass Above 200 Day Moving AverageHere's Why - MarketBeat
Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid (NASDAQ:OMER) - Seeking Alpha
What technical signals suggest for Omeros Corporation stockMarket Performance Recap & Real-Time Volume Trigger Notifications - newser.com
Omeros Corporation Stock Analysis and ForecastInsider Selling Patterns & Free Stock Trading Workshops - earlytimes.in
Is Omeros Corporation stock cheap compared to fundamentalsIPO Watch & Technical Entry and Exit Tips - newser.com
Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN
Omeros (NASDAQ:OMER) Shares Down 5.6%Should You Sell? - MarketBeat
Here's Why Shares in Theravance Biopharma Exploded Today - AOL.com
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - AOL.com
How strong is Omeros Corporation stock revenue growthBuy Signal & Fast Exit/Entry Strategy Plans - newser.com
Omeros Corporation Azioni (OMER) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):